Genomic Research in AAT-Deficiency and Sarcoidosis study (GRADS) Cooperative Research Project Grant: Clinical Centers (U01)

Post Date

February 2nd 2011

Application Due Date

May 17th 2011

Funding Opportunity Number

RFA-HL-12-013

CFDA Number(s)

93.838

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $12000000

• Award Range:

  $None - $None

Grant Description

The purpose of this funding opportunity announcement (FOA), issued by NHLBI, NIH, is to invite applications to participate in the NHLBI Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) program, which will assemble a multidisciplinary team of investigators to conduct state-of-art genomic, microbiomics and phenotypic studies of two serious and understudied conditions that affect the lungs: Alpha-1 Antitrypsin Deficiency (AAT) and sarcoidosis. GRADS will include up to eight Clinical Centers and one Genomics and Informatics Center (GIC). This FOA solicits applications for Clinical Centers and runs in parallel with a separate FOA that solicits applications for the GIC (see RFA-HL-12-014). The GRADS Clinical Centers will participate in a study-wide protocol by enrolling, clinically and immunologically phenotyping participants, and collecting and processing biospecimens to be shipped to the GIC for genomics and microbiomics analyses. Additionally, each Clinical Center will develop a clinic-specific research protocol aimed at identifying pathogenetic mechanisms or predictors of AAT or sarcoidosis disease development/progression. Collectively the GRADS Clinical Centers will create a program-wide cohort of approximately 400 AAT and approximately 200 sarcoidosis subjects and controls. Up to 8 Clinical Centers will be funded, each led by one or more Investigators with expertise in AAT, sarcoidosis, pulmonary medicine, immunology, genomics or cell biology. A Steering Committee of all the Clinical Center Principal Investigators will be organized by the GIC (see RFA-HL-12-014) to develop the study-wide protocol(s) and monitor study operations.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-12-013.html